natgillin/translations-raw huggingface dataset:
Caution should be taken when using fluoroquinolones, including levofloxacin, in patients with known risk factors for prolongation of the QT interval (see sections 4.5, 4.8 and 4.9) such as, for example: 
Fluorokinolone, vključno z levofloksacinom, je treba previdno uporabljati pri bolnikih z znanimi dejavniki tveganja za podaljšanje intervala QT (glejte poglavja 4.5, 4.8 in 4.9), na primer pri:
Effect of levofloxacin on other medicinal products 
Učinek levofloksacina na druga zdravila
Inhale the contents of one ampoule (240 mg) twice a day using the Zirela Nebuliser System. 
Vsebino ene ampule (240 mg) inhalirajte dvakrat na dan s pomočjo sistema nebulatorja Zirela.
Systemic levofloxacin 
Sistemski levofloksacin
The weight-based dosing scheme resulted in consistent serum and sputum PK exposure across the range of ages (7 to 16 years old) and weights (22 to 61 kg) observed in the study. 
Režim odmerjanja na podlagi telesne mase je povzročil skladno FK izpostavljenost v serumu in sputumu za vse razpone starosti (7 do 16 let) in telesne mase (22 do 61 kg), opazovane v študiji.
If you experience breathing difficulties after using Quinsair, your doctor may prescribe you an inhaler containing a bronchodilator medicine (e.g. salbutamol). 
Če se po uporabi zdravila Quinsair pojavijo težave z dihanjem, vam lahko zdravnik predpiše inhalacijo z bronhodilatatorjem (npr. salbutamol).
Symptoms include: - Loss of appetite - Yellowing of the skin and eyes (jaundice) - Dark coloured urine - Itching - Tenderness (pain) around the stomach (abdomen) 
Simptomi vključujejo: - izgubo apetita - porumenelost kože in oči (zlatenica) - temno obarvan urin - srbenje - občutljivost (bolečino) okoli trebuha (abdomna)
Study 209 (Core Phase) was a randomised, open-label, parallel group, active-controlled, non-inferiority study comparing Quinsair to tobramycin inhalation solution (TIS) over 3 treatment cycles. 
Študija 209 (osrednja faza) je bila randomizirana, odprta študija neinferiornosti z vzporednimi skupinami, nadzorovana z zdravilno učinkovino, v kateri so zdravilo Quinsair primerjali z raztopino tobramicina za inhaliranje v 3 ciklih zdravljenja.
Certain tests (e.g. to confirm tuberculosis or screening for strong painkillers) may give false results whilst you are being treated with Quinsair. 
Rezultati nekaterih preiskav (npr. za potrditev tuberkuloze ali presejalni testi za močne analgetike) so lahko med zdravljenjem z zdravilom Quinsair napačni.
Each treatment cycle included 28 days of treatment with Quinsair 240 mg twice daily or TIS 300 mg twice daily followed by 28 days without inhaled antibiotics. 
Vsak cikel zdravljenja je vključeval 28 dni zdravljenja z zdravilom Quinsair 240 mg dvakrat na dan ali raztopino tobramicina za inhaliranje (TIS) 300 mg dvakrat na dan, ki mu je sledilo 28 dni brez inhaliranja antibiotikov.
As with all quinolones, disturbances in blood glucose, including both hypoglycaemia and hyperglycaemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycaemic agent (e.g. glibenclamide) or with insulin. 
Tako kot pri vseh kinolonih so poročali o motnjah glukoze v krvi, vključno s hipoglikemijo in hiperglikemijo, običajno pri sladkornih bolnikih, ki so se sočasno zdravili s peroralnim hipoglikemičnih zdravilom (npr. glibenklamidom) ali z insulinom.
However, there is variability in the systemic exposures observed which means that serum levels of levofloxacin following inhalation of Quinsair may sometimes fall within the range of levels observed following systemic administration of comparable doses. 
Vendar pa so opazili variabilnost pri sistemskih izpostavljenostih, kar pomeni, da lahko ravni levofloksacina v serumu po inhaliranju zdravila Quinsair včasih padejo v razpon ravni, ki so jih opazili po sistemski uporabi primerljivih odmerkov.
- Inflammation of a tendon causing pain, stiffness and/or swelling in the joints (tendonitis). 
- Vnetje tetive, ki povzroči bolečino, togost in/ali oteklost sklepov (tendinitis).
- Glucose-6-phosphate dehydrogensae deficiency Quinolone antibiotics, such as Quinsair, can cause patients with glucose-6-phosphate dehydrogenase deficiency (a rare hereditary disease) to be prone to blood complications leading to a sudden rise in body temperature, yellowing of the skin and mucous membranes, dark coloured urine, paleness, tiredness, heavy, fast breathing and a weak, rapid pulse. 
- Pomanjkanje glukoza-6-fosfat-dehidrogenaze Kinolonski antibiotiki, kot je zdravilo Quinsair, lahko pri bolnikih s pomanjkanjem glukoza-6-fosfat-dehidrogenaze (redko dedno boleznijo) povzročijo nagnjenost h krvnim zapletom, ki vodijo v nenadno povečanje telesne temperature, porumenelost kože in sluznic, temen urin, bledico, utrujenost, težko, hitro dihanje in šibek, hiter utrip.
These two placebo-controlled studies showed that 28 days of treatment with Quinsair 240 mg twice daily resulted in significant improvement in relative change from baseline in FEV1 percent predicted compared to placebo (see Table 1). 
Ti dve s placebom nadzorovani študiji sta pokazali, da je 28 dni zdravljenja z zdravilom Quinsair 240 mg dvakrat na dan povzročilo značilno izboljšanje relativne spremembe od izhodišča v napovedanem odstotku FEV1 v primerjavi s placebom (glejte preglednico 1).
In very rare cases, these have progressed to suicidal thoughts and self-endangering behavioursometimes after only a single dose of levofloxacin (see section 4.8). 
V zelo redkih primerih so se psihotične reakcije stopnjevale vse do pojava samoogrožajočega vedenja in samomorilnih misli - včasih tudi po samo enkratnem odmerku levofloksacina (glejte poglavje 4.8).
What Quinsair is and what it is used for What you need to know before you use Quinsair How to use Quinsair 
Kaj je zdravilo Quinsair in za kaj ga uporabljamo Kaj morate vedeti, preden boste uporabili zdravilo Quinsair Kako uporabljati zdravilo Quinsair Možni neželeni učinki
Figure 1 3) Close the medicine reservoir by aligning the tabs of the medicine cap with the slots of the reservoir (a). 
Slika 1 3) Zaprite vsebnik za zdravilo tako, da poravnate jezičke pokrova za zdravilo z zarezami na vsebniku (a).
The outer carton box also contains one Zirela Nebuliser Handset packaged in its own carton box with the Manufacturer's Instruction for Use. 
Zunanja škatla vsebuje tudi en nebulator Zirela z navodili izdelovalca za uporabo, pakiran v ločeno škatlo.
It should only be used to treat lung infections caused by Pseudomonas aeruginosa. 
Uporablja se lahko le za zdravljenje pljučne okužbe, ki jo povzroča bakterija Pseudomonas aeruginosa.
Taking Quinsair at the same time as these medicines could affect how your kidneys deal with the medicine which is particularly important if you suffer from kidney problems. 
Uporaba zdravila Quinsair sočasno s temi zdravili lahko vpliva na način, na katerega ledvice predelajo nekatera zdravila, kar je zlasti pomembno, če imate težave z ledvicami.
Table 2: Results for the primary and key secondary endpoints in the active-controlled efficacy and safety study of Quinsair in patients with CF 
Preglednica 2: Rezultati za primarne in ključne sekundarne opazovane dogodke v študiji učinkovitosti in varnosti zdravila Quinsair pri bolnikih s CF, nadzorovani z zdravilno učinkovino
If for any reason you must stop the treatment before it's finished, press and hold the controller's on/off button for one second. 
Če morate zaradi kakršnega koli razloga zdravljenje ustaviti pred zaključkom, pritisnite in eno sekundo držite gumb za vklop/izklop na krmilniku.
At the first sign of pain or inflammation of a tendon (for example in your ankle, wrist, elbow, shoulder or knee), stop taking Quinsair, contact your doctor and rest the painful area. 
Ob prvem znaku bolečine ali vnetja tetive (na primer v gležnju, zapestju, komolcu, rami ali kolenu) prenehajte jemati zdravilo Quinsair, posvetujte se z zdravnikom in pustite, da boleči predel počiva.
Quinsair can interfere with the effects of these medicines. 
Zdravilo Quinsair lahko vpliva na učinek teh zdravil.
More detailed instructions are available in the Package Leaflet and device Manufacturer's Instructions for Use. 
Podrobnejša navodila najdete v navodilu za uporabo in v navodilih za uporabo proizvajalca pripomočka.
An in vitro study indicated a low potential for interaction between levofloxacin and CYP2C9 substrates. 
Substrati CYP2C9 Študija in vitro je pokazala nizek potencial za interakcije med levofloksacinom in substrati CYP2C9.
LS mean [95% CI]: 1.86 [-0.66, 4.39] c 
Povprečje LS [95-% IZ]: 1,86 [-0,66; 4,39] c
Each 28-day pack of Quinsair contains one box of 56 (14 sachets of 4) ampoules and one box holding a Zirela Nebuliser Handset with the Manufacturer's Instructions for Use. 
Vsako 28-dnevno pakiranje zdravila Quinsair vsebuje eno škatlo s 56 (14 vrečic s po 4) ampulami in eno škatlo z nebulatorjem Zirela z navodili izdelovalca za uporabo.
Established susceptibility breakpoints for systemic (oral or intravenous) administration of levofloxacin are not applicable to delivery by inhalation. 
Ugotovljene mejne vrednosti občutljivosti za sistemsko (peroralno ali intravensko) dajanje levofloksacina ne veljajo za dostavo zdravila z inhaliranjem.
The apparent clearance (CL/F) of levofloxacin following inhalation of Quinsair 240 mg twice daily is 31.8 +/- 22.4 L/hour. 
Navidezni očistek (CL/F) levofloksacina po inhaliranju zdravila Quinsair 240 mg dvakrat na dan je 31,8 +/- 22,4 l/uro.
Studies using systemic administration of levofloxacin show that the pharmacokinetics of levofloxacin are affected by renal impairment; with decreasing renal function (estimated creatinine clearance < 50 ml/min), renal elimination and clearance are decreased, and elimination half-life increased. 
Študije s sistemskim dajanjem levofloksacina so pokazale, da ledvična okvara vpliva na farmakokinetiko levofloksacina; z zmanjšanim delovanjem ledvic (ocenjeni očistek kreatinina < 50 ml/min) sta se ledvično izločanje in očistek zmanjšala, razpolovni čas izločanja pa se je povečal.
8) Once treatment is complete, disconnect the controller and take apart the Zirela Nebuliser Handset for cleaning and disinfecting. 
8) Po koncu zdravljenja odklopite krmilnik in razstavite nebulator Zirela, da ga očistite in razkužite.
INFORMATION IN BRAILLE Quinsair 
PODATKI V BRAILLOVI PISAVI Quinsair
Levofloxacin did not induce gene mutations in bacterial or mammalian cells but did induce chromosome aberrations in Chinese hamster lung cells in vitro. 
Levofloksacin ni povzročil genskih mutacij bakterijskih celic ali celic sesalcev, vendar je in vitro povzročil kromosomske aberacije pljučnih celic kitajskega hrčka.
- The other ingredients are magnesium chloride hexahydrate and water for injections. 
- Drugi sestavini zdravila sta magnezijev klorid heksahidrat in voda za injekcije.
Bronchospasm is a complication associated with inhaled therapies including Quinsair (see section 4.8). 
Bronhospazem je zaplet, povezan z inhalacijskim zdravljenjem, vključno z zdravilom Quinsair (glejte poglavje 4.8).
CI = Confidence interval; FEV1 = forced expiratory volume in 1 second; ITT = intent-to-treat (all patients randomised); P = P-value; SD = standard deviation; SE = standard error; TIS = tobramycin inhalation solution. 
IZ = interval zaupanja; FEV1 = forsirani ekspiratorni volumen (forced expiratory volume) v 1 sekundi; ITT = namen zdravljenja (intent to treat) (vsi randomizirani bolniki); P = vrednost P; SD = standardni odklon (standard deviation); SE = standardna napaka (standard error); TIS = raztopina tobramicina za inhaliranje (tobramycin inhalation solution).
A total of 88 patients received at least 1 dose of Quinsair in Study 209 (Extension Phase), 32 of these had received TIS and 56 of these had received Quinsair in the Core Phase. 
Skupaj 88 bolnikov je prejelo vsaj 1 odmerek zdravila Quinsair v študiji 209 (faza podaljška), med njimi jih je v osrednji fazi 32 prejelo raztopino tobramicina za inhaliranje in 56 zdravilo Quinsair.
After it has completely turned itself off and when you are ready to restart, press and hold the on/off button for one second again. 
Ko se povsem izklopi, vi pa ste pripravljeni za ponoven začetek zdravljenja, ponovno pritisnite gumb za vklop/izklop in ga eno sekundo držite.
Effect of other medicinal products on levofloxacin 
Učinek drugih zdravil na levofloksacin
Reduced bacterial permeability (common in P. aeruginosa) and efflux mechanisms may also confer or contribute to resistance. 
Do odpornosti lahko privedejo ali k njej prispevajo tudi zmanjšana bakterijska prepustnost (pogosta pri P. aeruginosa) in iztočni mehanizmi.
Do not inhale the contents of more than one ampoule to make up for a missed dose. 
Ne inhalirajte vsebine več kot ene ampule, da bi nadomestili izpuščeni odmerek.
Tell your doctor if you notice any skin reactions after using Quinsair. 
Obvestite zdravnika, če po uporabi zdravila Quinsair opazite kakršne koli kožne reakcije.
Table 3: Comparison of mean (SD) multiple dose levofloxacin pharmacokinetic parameters following Quinsair administration by inhalation to patients with CF and following oral and intravenous administration of levofloxacin to healthy adult volunteers 
Preglednica 3: Primerjava povprečnih (SD) farmakokinetičnih parametrov večkratnih odmerkov levofloksacina po uporabi zdravila Quinsair z inhaliranjem pri bolnikih s CF in po peroralnem in intravenskem dajanju levofloksacina zdravim odraslim prostovoljcem
Patients with latent or actual defects in glucose-6-phosphate dehydrogenase activity may be prone to haemolytic reactions when treated with quinolone antibacterial agents. 
Bolniki z latentnimi ali izraženimi motnjami aktivnosti glukoza-6-fosfat-dehidrogenaze so med zdravljenjem s kinolonskimi protibakterijskimi zdravili lahko nagnjeni k hemolitičnim reakcijam.
ECG monitoring should be undertaken because of the possibility of QT interval prolongation. 
Zaradi možnega podaljšanja intervala QT je treba opraviti EKG.
If you stop using Quinsair Do not stop using Quinsair without first talking to your doctor as your lung infection may worsen. 
Če ste prenehali uporabljati zdravilo Quinsair Zdravila Quinsair ne prenehajte uporabljati, ne da bi se prej posvetovali z zdravnikom, saj se lahko pljučna okužba poslabša.
Clinical pharmacology studies have shown that the pharmacokinetics of levofloxacin were not affected to any clinically relevant extent when levofloxacin was administered together with the following active substances: calcium carbonate, digoxin, glibenclamide and ranitidine. 
Klinično-farmakološke študije so pokazale, da na farmakokinetiko levofloksacina ni klinično pomembno vplivala hkratna uporaba z nobeno od naslednjih zdravilnih učinkovin: kalcijevim karbonatom, digoksinom, glibenklamidom, ranitidinom.
Due to the limited extent of levofloxacin metabolism in the liver, the pharmacokinetics of levofloxacin are not expected to be affected by hepatic impairment. 
Zaradi omejenega obsega presnove levofloksacina v jetrih se ne pričakuje, da bi jetrna okvara vplivala na farmakokinetiko levofloksacina.
Therefore, if levofloxacin has to be used in these patients, potential occurrence of haemolysis should be monitored. 
Če morajo taki bolniki jemati levofloksacin, je treba pri njih spremljati možnost pojava hemolize.
OFF Quinsair Do not use it for the next 28 days 
BREZ zdravila Quinsair Naslednjih 28 dni zdravila ne uporabljajte
Table 1: FEV1 Percent predicted relative change from baseline to Day 28 in placebo-controlled efficacy and safety studies of Quinsair in patients with CF 
Preglednica 1: Relativna sprememba v napovedanem odstotku FEV1 od izhodišča do 28. dne v študijah učinkovitosti in varnosti zdravila Quinsair, nadzorovanih s placebom, pri bolnikih s CF
- Do not use Quinsair if you notice that it is cloudy or there are particles in the solution. 
- Zdravila Quinsair ne uporabljajte, če opazite, da je motno ali da so v raztopini delci.
Quinolone antibiotics, including Quinsair, may cause seizures or convulsions (fits). 
Kinolonski antibiotiki, vključno z zdravilom Quinsair, lahko povzročijo epileptične napade ali konvulzije (krče).
You use Quinsair every day for 28 days, then take a 28-day break, during which you do not inhale any Quinsair. 
Zdravilo Quinsair uporabljajte 28 dni vsak dan, nato pa sledi 28-dnevna prekinitev, med katero zdravila Quinsair ne inhalirajte.
All patients had also received at least 3 courses of TIS in the 12 months prior to entry into the study, but none in the 28 days immediately preceding study entry. 
Vsi bolniki so v 12 mesecih pred vstopom v študijo prejeli tudi vsaj 3 cikle raztopine tobramicina za inhaliranje, vendar ne v 28 dneh tik pred vstopom v študijo.
The pharmacokinetics of levofloxacin following inhalation of Quinsair 240 mg twice daily were investigated in paediatric patients with CF aged 12 years and older and weighing ≥ 30 kg. A population PK model based on sparse sampling determined that levofloxacin serum concentrations were comparable between paediatric and adult patients following 28 days of treatment. 
Farmakokinetiko levofloksacina po inhaliranju zdravila Quinsair 240 mg dvakrat na dan so preučili pri pediatričnih bolnikih s CF, starih 12 let ali več, s telesno maso ≥ 30 kg. Na modelu populacijske FK na podlagi redkih vzorcev so ugotovili, da so bile koncentracije levofloksacina v serumu po 28 dneh zdravljenja med pediatričnimi in odraslimi bolniki primerljive.
The proportion of patients who received Quinsair throughout Study 209 Core and Extension Phases (with a highest levofloxacin MIC P. aeruginosa isolate exceeding 1 µg/ml) was similar at the end of treatment during Cycles 1 and 3 in the Core Phase (76.6% to 83.3%) and at the end of treatment during Cycles 4 to 6 in the Extension Phase (77.8% to 87.5%). 
Delež bolnikov, ki so zdravilo Quinsair prejemali ves čas osnovne faze in faze podaljška študije 209 (z največjo MIC levofloksacina za izolat P. aeruginosa več kot 1 µg/ml), je bil podoben ob koncu zdravljenja med 1. in 3. ciklom v osrednji fazi (76,6% do 83,3%) in ob koncu zdravljenja med 4. in 6. ciklom v fazi podaljška (77,8% do 87,5%).
Ciclosporin The half-life of ciclosporin was increased by 33% when coadministered with levofloxacin. 
Ciklosporin Razpolovni čas ciklosporina se je med sočasno uporabo levofloksacina podaljšal za 33%.
The use of levofloxacin should be avoided in patients who have experienced serious adverse reactions in the past when using quinolone or fluoroquinolone containing products (see section 4.8). 
Uporabi levofloksacina se je treba izogibati pri bolnikih, pri katerih so se v preteklosti med uporabo zdravil, ki vsebujejo kinolone ali fluorokinolone, pojavili resni neželeni učinki (glejte poglavje 4.8).
Uncommon: may affect up to 1 in 100 people - Fungal infection of the mouth - Low numbers of red cells in the blood (anaemia) or the cells in the blood that help it clot 
Občasni: pojavijo se lahko pri do 1 od 100 bolnikov - glivična okužba ust - majhno število rdečih krvnih celic (anemija) ali krvnih celic, ki pomagajo pri strjevanju krvi
However, a pronounced lowering of the cerebral seizure threshold may occur when quinolones are given concurrently with theophylline, non-steroidal anti-inflammatory drugs, or other substances which lower the seizure threshold. 
Vendar se lahko prag za cerebralne napade izrazito zniža pri sočasni uporabi kinolonov ter teofilina, nesteroidnih protivnetnih zdravil ali drugih zdravil, ki znižujejo prag za napade.
Patients weighing 22 to 30 kg received 180 mg levofloxacin/day and patients weighing ˃ 30 kg received 240 mg levofloxacin/day. 
Bolniki s telesno maso 22 do 30 kg so prejeli 180 mg levofloksacina/dan in bolniki s telesno maso ˃ 30 kg so prejeli 240 mg levofloksacina/dan.
c Non-inferiority was tested using a pre-specified, fixed non-inferiority margin of 4% at Day 28 of Cycle 1. d Estimates were obtained from a Cox proportional hazards regression model. 
c Neinferiornost je bila testirana z vnaprej specificirano, 4-odstotno fiksno mejo neinferiornosti na 28. dan
Rhabdomyolysis, Tendon rupture, Ligament rupture, Muscle rupture, Arthritis 
mišična oslabelost rabdomioliza, pretrganje kite, pretrganje ligamenta, pretrganje mišice, artritis
ON Quinsair Use it twice a day for 28 days 
Z zdravilom Quinsair Zdravilo 28 dni uporabljajte dvakrat na dan
Quinsair is taken in alternating cycles of 28 days on treatment followed by 28 days off treatment. 
Zdravilo Quinsair se jemlje v izmeničnih ciklih z 28-dnevnim zdravljenjem, ki mu sledi 28-dnevno obdobje brez zdravljenja.
The mean apparent volume of distribution of levofloxacin in serum is approximately 250 L following inhalation of Quinsair 240 mg twice daily. 
Povprečni navidezni volumen porazdelitve levofloksacina v serumu je približno 250 l po inhaliranju zdravila Quinsair 240 mg dvakrat na dan.
The maximal plasma concentration (Cmax) of levofloxacin following administration by inhalation occurred at approximately 0.5-1 hour post-dose. 
Največje koncentracije levofloksacina v plazmi (Cmax) po inhaliranju so nastopile približno 0,5-1 uro po odmerjanju.
CI = Confidence interval; FEV1 = forced expiratory volume in 1 second; ITT = intent to treat (all patients randomised); P = P value; SD = standard deviation; SE = standard error; ANCOVA = analysis of covariance. 
CI = interval zaupanja (confidence interval); FEV1 = forsirani ekspiratorni volumen (forced expiratory volume) v 1 sekundi; ITT = namen zdravljenja (intent to treat) (vsi randomizirani bolniki); P = vrednost P; SD = standardni odklon (standard deviation); SE = standardna napaka (standard error); ANCOVA = analiza kovariance.
Levofloxacin is primarily excreted unchanged in the urine and metabolism is minimal (see section 5.2). 
Levofloksacin se primarno nespremenjen izloča v urinu in se presnovi v zelo majhni meri (glejte poglavje 5.2).
Quinolone antibiotics, including Quinsair, may cause levels of glucose in the blood to be either too high or too low. 
Kinolonski antibiotiki, vključno z zdravilom Quinsair, lahko povzročijo previsoke ali prenizke ravni glukoze v krvi.
LS mean [95% CI]: 
Povprečje LS [95-% IZ]:
If a dose is missed, it should be taken as soon as the patient remembers providing that at least an 8 hour interval is allowed before inhaling the next dose. 
Če bolnik odmerek izpusti, ga naj vzame takoj, ko se spomni, pri čemer naj upošteva vsaj 8-urni interval pred inhaliranjem naslednjega odmerka.
Levofloxacin is an antibacterial agent of the fluoroquinolone class and is the S (-) enantiomer of the racemic active substance ofloxacin. 
Levofloksacin je protibakterijsko zdravilo iz skupine fluorokinolonov in je S(-) enantiomer racemata zdravilne učinkovine ofloksacina.
Quinsair contains an antibiotic medicine called levofloxacin. 
Zdravilo Quinsair vsebuje antibiotik, imenovan levofloksacin.
You should not take fluoroquinolone/quinolone antibacterial medicines, including Quinsair, if you have experienced any serious adverse reaction in the past when taking a quinolone or fluoroquinolone. 
Protibakterijskih zdravil, ki vsebujejo fluorokinolone/kinolone, vključno z zdravilom Quinsair, ne smete jemati, če so se vam pri jemanju fluorokinolonov ali kinolonov že kdaj pojavili kakršni koli resni neželeni učinki.
In addition, 14 children with CF (≥ 6 to < 12 years old) and 13 adolescents with CF (≥ 12 to < 17 years old) received Quinsair 180 mg or 240 mg once daily for 14 days. 
Poleg tega je 14 otrok s CF (≥ 6 do < 12 let) in 13 mladostnikov s CF (≥ 12 do < 17 let) 14 dni enkrat na dan prejemalo 180 mg ali 240 mg zdravila Quinsair.
It takes about 5 minutes to inhale the medicine using the nebuliser. 
Inhaliranje zdravila z nebulatorjem traja približno 5 minut.
The safety and efficacy of Quinsair in children aged ˂ 18 years old have not yet been established. 
Varnost in učinkovitost zdravila Quinsair pri otrocih, starih < 18 let, še nista bili dokazani.
Once an ampoule is opened, the contents should be used immediately. 
Ko boste ampulo odprli, morate vsebino uporabiti takoj.
Pharmacokinetic studies with Quinsair in patients with hepatic impairment have not been conducted. 
Farmakokinetičnih študij z zdravilom Quinsair pri bolnikih z jetrno okvaro niso izvedli.